title: Single agent vs combination chemotherapy in the treatment of ovarian cancer.
abstract: One hundred and eight patients with Stage III or IV epithelial ovarian cancers were randomly allocated to treatment with either melphalan or the combination of Actinomycin-D, 5-fluorouracil, and cyclophosphamide (ACFUCY). Those patients receiving the ACFUCY combination had a higher objective response rate and a statistically significantly lower progression rate. The ACFUCY combination gave a higher incidence of severe toxicity.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003609:Dactinomycin / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D003609:Dactinomycin; D003520:Cyclophosphamide; D008558:Melphalan; D005472:Fluorouracil